Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 56Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Myelodysplastic Syndromes 41Leukemia, Lymphocytic, Chronic, B-Cell 30Lymphoma, Non-Hodgkin 27Multiple Myeloma 22Leukemia, Myelogenous, Chronic, BCR-ABL Positive 22Hodgkin Disease 20Leukemia 17Myeloproliferative Disorders 16Recurrence 15Lymphoma, Follicular 15Leukemia, Biphenotypic, Acute 15Melanoma 14Lymphoma, Mantle-Cell 14Lymphoma 14Leukemia, Myelomonocytic, Chronic 14Lymphoma, Large B-Cell, Diffuse 13Hematologic Neoplasms 13Burkitt Lymphoma 11Anemia, Refractory, with Excess of Blasts 11Lymphoma, B-Cell, Marginal Zone 10Lymphoma, B-Cell 10Primary Myelofibrosis 8Neoplasm, Residual 7Neoplasm Metastasis 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Neoplasms 6Graft vs Host Disease 6

Interventions

Lenalidomide 7Dexamethasone 5daratumumab 4Calcium Dobesilate 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Curcumin 3isatuximab 2iberdomide 2Leflunomide 2pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1fludarabine phosphate 1fludarabine 1citarinostat 1Watchful Waiting 1Urination 1Stem Cell Transplantation 1Resistance Training 1Propranolol 1Probiotics 1Peripheral Blood Stem Cell Transplantation 1PVX-410 vaccine 1Observation 1Metformin 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × fludarabine phosphate × 1 year × Clear all
NCT05767359 2026-03-12

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
20 enrolled
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡